Early Detection Research Network


This biomarker is also known as:
  • Large fibroblast proteoglycan,
  • versican proteoglycan,
  • GHAP,
  • Chondroitin sulfate proteoglycan core protein 2,
  • VCAN,
  • versican,
  • PG-M,
  • chondroitin sulfate proteoglycan 2,
  • Glial hyaluronate-binding protein,
  • WGN1,
  • versican core protein,
  • CSPG2,
  • ERVR,
  • WGN,


VCAN, or CSPG2, a large chondroitin sulfate proteoglycan, is a major component of the extracellular matrix. This secreted protein is involved in cell adhesion, proliferation, migration and angiogenesis and plays a central role in tissue morphogenesis and maintenance. It is may play a role in intercellular signaling. Mutations in the CSPG2 gene are the cause of Wagner syndrome type 1. Multiple transcript variants encoding different isoforms have been found for this gene.


There are no datasets associated with this biomarker.

QA State: Curated
Type: Protein

The following organs have data associated with this biomarker…


Phase: Three
QA State: Under Review


VCAN (CSPG2) was shown to localize to vascular-like structures in ovarian cancer but not in normal ovaries.

Performance Comment

VCAN, or CSPG2, was one of 13 genes out of 50 selected for further validation in PMID:21617380. Average expression of VCAN was significantly higher in epithelial ovarian cancer tumors than any other normal tissue tested.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.